MORF News and Press, Morphic Holding Inc. From 06/21/22

Gainers: Novavax (NVAX) +259%. Precision BioSciences (DTIL) +114%. Amazon.com (AMZN) +39%. Adobe (ADBE) +32%. Paratek Pharmaceuticals (PRTK) +15%. Losers:Euronet Worldwide (EEFT) -5%. Seres Therapeutics (MCRB) -5%. Sanderson Farms (SAFM) -5%. Morphic Holding (MORF) -4%. Redbox Entertainm...

WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Bruce Rogers, Ph.D., President of Morphic, will gi...

WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Joanne Gibbons has been named Senior Vice Presi...

WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will participate in ...

WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced two key executive appointments. Dr. Bruce Rogers has...

Morphic press release (NASDAQ:MORF): Q1 GAAP EPS of -$0.85 misses by $0.04. Revenue of $2.38M (-27.0% Y/Y) misses by $0.84M. Shares -1.06% PM. For further details see: Morphic GAAP EPS of -$0.85 misses by $0.04, revenue of $2.38M misses by $0.84M

Initiated EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Described new understanding of α4β7-expressing immune cells and MORF-057 dose response in oral presentation at ECCO 2022 Announced key appointments and advancements in leadersh...

Shares of Morphic Holding (NASDAQ:MORF) are up 7% in Tuesday afternoon trading on volume more than 5 times its normal daily average. As of 342p ET, more than 1.4M shares had traded hands. On a normal day, volume is ~264K. The oral small-molecule integrin therapeutics developer has o...

Gainers: Evoke Pharma (EVOK) +151%. Avadel Pharmaceuticals (AVDL) +26%. Arch Resources (ARCH) +21%. Magnachip Semiconductor (MX) +20%. TradeUP Global (TUGCU) +20%. Jiuzi Holdings (JZXN) +19%. Forge Global Holdings (FRGE) +18%. Morphic Holding (MORF) +16%. Flexsteel Industries (FLXS) +15%. Sky...

Dr. Brihad Abhyankar named Vice President of Clinical Development, deeply experienced GI drug development leader Aaron Pelta promoted to Senior Vice President, Business and Corporate Development; leading portfolio, commercial, and partnering strategy WALTHAM, Mass., April 06, ...